Introduction
============

Etomidate is considered an almost ideal induction agent because of the rapid onset and the predictable short duration of action in combination with minimal implications for the cardiovascular and pulmonary system \[[@B1]\]. These effects and benefits are even more important in high-risk cardiac surgery patients. However, soon after licensing of etomidate for long-term sedation and anesthesia in 1972, an increased mortality in intensive care patients resulted in recommendations to stop long-term use \[[@B2]-[@B4]\]. Even a single dose of etomidate inhibits transiently adrenal mitochondrial 11-β-hydroxylase activity with consecutive adrenal suppression \[[@B5],[@B6]\]. Ever since, intensive care, emergency, and anesthesia communities have been discussing the use of even a single dose of etomidate controversially. Various studies and meta-analyses found either an increased \[[@B7]-[@B10]\] or an equal \[[@B11]-[@B17]\] risk of mortality and risk variables after administration of etomidate in critically ill patients with sepsis. In trauma patients, an increased susceptibility to pneumonia is attributed to etomidate \[[@B18]\].

Etomidate is frequently used for anesthesia induction ahead of cardiac surgery. In this context, smaller studies showed that etomidate is associated with increased vasopressor requirements \[[@B19]\]. Other authors report a relative adrenal insufficiency and deny an increase of vasopressor requirements \[[@B20]\]. In a retrospective analysis of 3,127 patients receiving etomidate or propofol, Wagner and colleagues \[[@B21]\] showed no increase in severe hypotension, in-hospital mortality, duration of hospital stay, intensive care unit (ICU) stay, and duration of mechanical ventilation. Further evidence for postoperative systemic inflammatory response syndrome (SIRS) due to adrenal insufficiency is of particular relevance for patients after on-pump cardiac surgery. It is well known that on-pump cardiac surgery per se is a risk factor for postoperative SIRS and infections \[[@B22]\]. The objective of our study was to determine differences in key clinical outcome parameters following anesthesia induction with administration of etomidate or an alternative induction regime. Analyzed parameters for clinical outcome were sepsis-associated serum parameters, duration of mechanical ventilation, morbidity scores, renal failure, length of ICU stay, and ICU and hospital mortality.

Materials and methods
=====================

Ahead of this study, the local ethics committee (Ethics Committee of Friedrich-Alexander University Erlangen-Nürnberg) confirmed that no further patients' consent and institutional ethical approval were required. This decision was based on the retrospective, descriptive, and anonymous study design and the fully closed patient files.

All anesthesia and ICU records from adult patients undergoing general anesthesia for major on-pump cardiac surgery at the university hospital in five consecutive years (January 2008 to December 2012) were analyzed retrospectively. The filed anesthesia records were retrieved from an electronic patient data management system (PDMS) (NarkoData Imeso, Hüttenberg, Germany) including an unambiguous and unique case identifier number (UCIN) (Figure [1](#F1){ref-type="fig"}). The UCIN is a pre-existing code of 13 digits to uniquely identify an individual case and is used to collect all available data from different PDMSs of a specific case to create the invoice for health insurance companies. Anonymized data were transferred to an MS Office 2010 Access® database (Microsoft Corporation, Redmond, WA, USA) including age, height, weight, Mallampati score, Acute Physiology and Chronic Health Evaluation II (APACHE II) score \[[@B23]\], Cormack and Lehane (CML) classification, priority of surgery, anesthesia drugs, and aortic clamping, bypass, and operation times. The postoperative ICU patient data were retrieved from the PDMS (ICM Dräger, Lübeck, Germany) and matched with the anesthesia data by using the UCIN. These data include laboratory parameters, duration of mechanical ventilation, length of ICU stay, ICU mortality, and Sequential Organ Failure Assessment (SOFA) score \[[@B24],[@B25]\]. The ICM data are redundantly stored in the hospital PDMSs (Lauris and Soarian; Siemens, Erlangen, Germany) to facilitate access also from the normal care wards to these data (laboratory test results). Additional data which are available only in the hospital PDMSs (Lauris® and Soarian®) were also transferred and matched with the study database by using the UCIN. The data abstractors were qualified and experienced in the field of medical data management. For every PDMS, a single abstractor worked independently and fully blinded to the purpose of the study. The complete data of an observed case could be seen by the investigator group only after the matching in the study database. After the matching with the UCIN, the date of birth of the patient in the two datasets was compared to get a secondary check for the correct match of the datasets. If the date of birth had not been identical in the datasets, the study database would have alerted the investigator to a data mismatch (plausibility control). However, such a mismatch was not observed in any of the cases of this study.

![**Flow chart showing the case selection and data collection of the study.** ICU, intensive care unit; PDMS, patient data management system.](cc13988-1){#F1}

Patients who reached the operation theatre already intubated and sedated were excluded from the analysis, as the anesthetic drugs used for intubation could not be verified in these cases. Patients with an ICU admission ahead of major cardiac surgery were also excluded from the analysis as their morbidity and mortality odds ahead of cardiac surgery may differ significantly from those of the other patients. For the same reason, cases with repetitive major cardiac surgery and off-pump coronary artery bypass grafting were excluded.

The cardiac surgery department contributing to this study provides a full spectrum of cardiac surgery for patients of every age, including heart transplantation and device surgery. The university hospital at Erlangen is a tertiary center with approximately 1,400 beds and provides about 900 on-pump cardiac surgery interventions per year, including around 250 interventions in pediatric cardiac surgery. In the cardiac surgery department, anesthetists have at least three years of professional experience and are under close supervision of senior physicians. Preoperative evaluation, induction, and maintenance of anesthesia as well as postoperative ICU treatment are performed in accordance with standard operating procedures (SOPs). The SOP for preoperative evaluation includes the documentation of the four-scale Mallampati test result \[[@B26]\]. Documentation of physical health status in accordance with the American Society of Anesthesiologists (ASA) was mandatory.

SOPs for anesthesia induction and maintenance demand a consistent approach, including arterial catheterization with local anesthesia, intravenous application of an opioid, a hypnotic drug, and a neuromuscular blocking agent. However, every anesthesiologist was free to vary the anesthetic drug regime for induction and maintenance. Etomidate (0.25 to 0.35 mg/kg) was the most commonly used hypnotic drug in this analysis. Alternatively, a combination of 1.5 to 2.0 mg/kg esketamine and 0.5 to 2 mg/kg propofol was administered for anesthesia induction. Cis-atracurium (0.15 to 0.2 mg/kg) was administered as standard neuromuscular blocking agent. In the case of a rapid sequence induction (RSI), 0.6 to 0.9 mg/kg rocuronium was given. The direct laryngeal view was graded in accordance with the four-scale CML classification \[[@B27]\]. Anesthesia was maintained with either continuous injection of propofol or inhalative application of sevoflurane which was also administered, in parts, in the pump circuit during cardiopulmonary bypass time. Continuous infusion of 0.4 to 0.8 μg/kg per hour sufentanil was the standard analgesic regime. All patients received continuous infusion of propofol at the end of surgery for transfer to the ICU and ongoing ICU sedation. Antimicrobial prophylaxis was performed by administration of a cephalosporine after the anesthesia induction and a repetitive dose after cardiopulmonary bypass. The antimicrobial regime remained unchanged during the study period. Admission SOP in the ICU for cardiac surgery patients includes hemogram and serum test of myocardial necrosis indicators like general creatinkinasis (CK), specific myocardial creatinkinasis (CK-MB), and troponin I (TROP) as well as inflammatory parameters like C-reactive protein (CRP). Procalcitonine (PCT) is not part of the standard blood testing but could be chosen by the attending physician for early detection of bacterial infection. The duration of mechanical ventilation was measured from ICU admission until extubation. Mechanical ventilation hours were summarized in cases of repetitive mechanical ventilation periods. SOFA score was obtained only when patients stayed more than 24 hours in the ICU.

Statistics
----------

Statistical processing was performed by using SPSS® 20.0 (IBM, Armonk, NY, USA; significance level *P* \<0.05). Gaussian distribution of continuous variables was tested by using the Kolmogorov-Smirnov test. If continuous variables show Gaussian distribution, they are expressed as mean value and standard error and were compared by using the two-tailed Student *t* test. Categorical variables are given as absolute number and percentage of occurrence. A univariate analysis of categorical variables was performed by using the chi-squared test. Multivariate analysis for categorical variables and Cox analysis for survival variables was conducted where meaningful. An *ad posteriori* sample size calculation with estimated mortality rates of 3% and 5%, a statistical power of 0.8, and a confidence interval of 95% revealed a required number of at least 1,506 cases to enclose.

Results
=======

The definitive analysis includes a total of 3,054 out of 3,212 available cases, indicating a dropout rate of 5%. A group of 1,775 (58%) patients received etomidate ahead of cardiac surgery to facilitate anesthesia induction and endotracheal intubation. A group of 1,279 patients (42%) did not receive etomidate. The underlying demographic and preoperative data are shown in Table [1](#T1){ref-type="table"}. There is a significantly higher number of female patients in the etomidate group: 554 (31%) versus 340 (27%) (*P* = 0.006). All other preoperative and demographic items show no significant difference.

###### 

Preoperative and demographic data of the two study groups

  **Categories**                    **Non-etomidate group**   **Etomidate group**   ***P*value**
  --------------------------------- ------------------------- --------------------- --------------
  Number of patients                1,279                     1,775                  
  Sex                                                                                
   Female                           340 (27%)                 554 (31%)             0.006
   Male                             939 (73%)                 1,221 (69%)           
  Age, years                        67.9 ± 0.3                67.8 ± 0.2            0.600
  Body mass index, kg/m^2^          28.2 ± 0.2 (24.8/30.7)    25.5 ± 0.2            0.994
  ASA score                                                                          
   1                                3 (0.2%)                  2 (0.1%)              0.413
   2                                31 (2%)                   59 (3%)               0.147
   3                                1,143 (89%)               1,548 (87%)           0.069
   4                                101 (8%)                  163 (9%)              0.212
   5                                1 (0.1%)                  3 (0.2%)              0.494
  APACHE II score                                                                    
                                    17.0 ± 0.2                16.7 ± 0.1            0.151
   Missing                          73 (5.7%)                 101 (5.7%)             
  Mallampati                                                                         
   1                                142 (11%)                 246 (14%)             0.024
   2                                884 (69%)                 1,139 (64%)           0.004
   3                                168 (13%)                 307 (17%)             0.002
   4                                15 (1%)                   16 (1%)               0.460
   Missing                          70 (6%)                   67 (4%)               0.025
  Pre-operative hemoglobin                                                           
   g/dL                             13,1 ± 0.6                13.0 ± 0.5            0.899
   Missing                          217 (17%)                 337 (19%)              
  Pre-operative creatinine                                                           
   mg/dL                            1.15 ± 0.2                1.15 ± 0.2            0.520
   Missing                          385 (30%)                 365 (21%)              
  Pre-operative creatinine kinase                                                    
   U/L                              119.1 ± 5.5               125.2 ± 5.7           0.055
   Missing                          483 (38%)                 487 (27%)              

Continuous variables are given as mean ± standard error, and categorical variables are presented as number (percentage). APACHE II, Acute Physiology and Chronic Health Evaluation II; ASA, American Society of Anesthesiologists.

Intraoperative data are shown in Table [2](#T2){ref-type="table"}. The rate of poor laryngoscopic view given as CML 3 or 4 in the etomidate group is significantly lower than in the non-etomidate group (4.5% versus 9.8%; *P* \<0.001). The rate of emergency cardiac surgery is significantly higher in the etomidate group. All other intraoperative items show no significant difference. A multivariate analysis revealed male gender, the absence of etomidate, and high Mallampati score as independent risk factors for poor laryngoscopic view given as CML 3 or 4 (Table [3](#T3){ref-type="table"}).

###### 

Intraoperative data of the two study groups

  **Categories**                      **Non-etomidate group**   **Etomidate group**   ***P*value**
  ----------------------------------- ------------------------- --------------------- --------------
  Number of patients                  1,279                     1,775                  
  Priority of surgery                                                                  
   Elective                           1,176 (92%)               1,562 (88%)           \<0.001
   Emergency                          103 (8%)                  213 (12%)             
  Cormack-Lehane                                                                       
   1                                  681 (53%)                 1,334 (75%)           \<0.001
   2                                  466 (36%)                 353 (20%)             \<0.001
   3                                  114 (9%)                  71 (4%)               \<0.001
   4                                  12 (1%)                   9 (0.5%)              0.154
   Missing                            4 (1%)                    5 (0.5%)              0.875
  Neuromuscular blocking agent                                                         
   Cisatracurium                      1,204 (94%)               1,572 (89%)           \<0.001
   Rocuronium                         30 (2%)                   182 (10%)             \<0.001
   Suxamethonium                      9 (1%)                    21 (1%)               0.185
   Missing                            36 (3%)                   0 (0%)                \<0.001
  Cut-to-suture time, minutes         198.2 ± 1.7               202.2 ± 1.6           0.138
  Bypass time, minutes                83.5 ± 1.0                87.1 ± 1.0            0.105
  Aortic clamping, minutes            49.0 ± 0.7                51.6 ± 0.6            0.299
  Mechanical ventilation, hours       19.69 ± 1.5               21.22 ± 1.3           0.355
  Intraoperative epinephrine, mg      102.0 ± 20.1              77.1 ± 14.2           0.054
  Intraoperative norepinephrine, mg   1,165.7 ± 108.8           1,178 ± 79.0          0.458

Continuous variables are given as mean ± standard error, and categorical variables are presented as number (percentage).

###### 

Multivariate analysis to identify risk factors for poor laryngoscopic view

  **Co-variable**                **Odds ratio (95%CI)**   ***P*value**
  ------------------------------ ------------------------ --------------
  Male gender                    0.87 (0.48-1.25)         \<0.001
  ASA score of 3 or 4            −0.12 (−0.93-0.69)       0.770
  MLP 3 or 4                     1.34 (1.04-1.64)         \<0.001
  Emergency surgery              0.07 (−0.40-0.55)        0.760
  Administration of etomidate    −0.89 (−1.17-0.59)       \<0.001
  Administration of rocuronium   0.04 (−0.59-0.67)        0.899

ASA, American Society of Anesthesiologists; CI, confidence interval; MLP, Mallampati Score.

The main results addressing mortality and ICU course are presented in Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. ICU discharge rate at the first postoperative day is significantly higher in the non-etomidate group than in the etomidate group: 694 (56%) versus 883 (51%) (*P* = 0.013). An isolated view on second postoperative day reveals significantly higher discharge rate of the etomidate group: 297 (17%) versus 158 (13%) (*P* \<0.001). Summation of postoperative days 1 and 2 shows that there is no difference between the two study groups: 852 (68%) versus 1,180 (68%) (*P* = 0.937). On subsequent postoperative days, there was no difference between the groups until the end of observation on day 5.

###### 

Postoperative data of the two study groups

  **Categories**                  **Non-etomidate group**   **Etomidate group**      ***P*value**
  ------------------------------- ------------------------- ------------------------ --------------
  Number of patients              1,279                     1,775                     
  CRP, mg/L                                                                           
   Missing                        140 (10.9%)               80 (4.5%)                 
   Day 1                          76.9 ± 1.2                77.0 ± 1.0               0.924
   Day 2                          183.8 ± 2.6               194.1 ± 2.2              0.382
   Day 3                          205.9 ± 3.8               211.5 ± 3.4              0.316
   Day 4                          189.7 ± 4.9               187.9 ± 4.3              0.340
   Day 5                          166.6 ± 6.5               150.9 ± 4.9              0.306
  PCT, ng/mL                                                                          
   Missing                        732 (57.2%)               963 (54.2%)               
   Day 1                          4.1 ± 0.4                 5.6 ± 0.5                0.053
   Day 2                          8.4 ± 0.9                 10.0 ± 1.1               0.090
   Day 3                          7.9 ± 0.9                 8.8 ± 0.9                0.312
   Day 4                          6.3 ± 0.9                 6.6 ± 0.9                0.673
   Day 5                          4.7 ± 0.6                 5.7 ± 0.7                0.254
  Leukocytes, 10^3^/μL                                                                
   Missing                        73 (5.7%)                 63 (3.5%)                 
   Day 1                          12.8 ± 0.2                11.7 ± 0.1               0.061
   Day 2                          11.9 ± 0.2                11.7 ± 0.2               0.327
   Day 3                          11.9 ± 0.3                11.7 ± 0.3               0.899
   Day 4                          11.5 ± 0.4                11.3 ± 0.4               0.969
   Day 5                          11.7 ± 0.5                11.3 ± 0.4               0.776
  CK                                                                                  
   U/L                            1347 ± 71                 1642 ± 86                0.002
   Missing                        390 (30.5%)               226 (12.7%)               
  CK-MB                                                                               
   U/L                            10.1 ± 0.2                10.0 ± 0.2               0.801
   Missing                        444 (34.7%)               292 (16.4%)               
  Troponin                                                                            
   μg/L                           9.8 ± 0.6                 11.5 ± 0.5               0.004
   Missing                        391 (30.5%)               230 (12.9%)               
  Hemodialysis                                                                        
   N                              8.8%                      10.2%                    0.190
   Hours                          105 ± 12                  112 ± 10                 0.861
  SOFA score                                                                          
   Missing                        655 (51.2%)               884 (49.8%)               
   Day 1                          7.9 ± 0.1                 7.9 ± 0.1                0.340
   Day 2                          7.2 ± 0.2                 7.3 ± 0.1                0.122
   Day 3                          7.4 ± 0.2                 7.3 ± 0.2                0.697
   Day 4                          8.3 ± 0.3                 8.2 ± 0.2                0.859
   Day 5                          8.8 ± 0.3                 8.4 ± 0.3                0.394
  Hospital days                   17.4 ± 0.6                18.7 (0.6%)              0.250
  ICU days                        2.5 ± 0.1                 2.6 ± 0.1                0.857
  ICU discharge                                                                       
   Day 1                          694 (56%)                 883 (51%)                0.013
   Day 2                          158 (13%) (∑852; 68%)     297 (17%) (∑1180; 68%)   0.937
   Day 3                          151 (12%) (∑1003; 80%)    205 (12%) (∑1385; 80%)   0.795
   Day 4                          80 (6%) (∑1083; 87%)      115 (7%) (∑1500; 87%)    0.898
   Day 5                          39 (3%) (∑1122; 90%)      51 (3%) (∑1551; 90%)     0.776
  ICU re-admission                70 (5.5%)                 102 (5.8%)               0.746
  7-day mortality                 39 (3.0%)                 64 (3.6%)                0.401
  30-day mortality                66 (5.2%)                 106 (6.0%)               0.337
  Overall in hospital mortality   82 (6.4%)                 121(6.8)                 0.657

Continuous variables are given as mean ± standard error, and categorical variables are presented as number (percentage). CK, creatinkinasis; CML, Cormack and Lehane; CRP, C-reactive protein; ICU, intensive care unit; PCT, procalcitonine; SOFA, Sequential Organ Failure Assessment.

###### 

Multivariate cox analysis with survival data

  **Co-variables**                                **Hazard ratio (95%CI)**   ***P*value**
  ----------------------------------------------- -------------------------- --------------
  Administration of etomidate                     1.1 (0.79-1.51)            0.602
  Body mass index of more than 40 kg/m^2^         1.25 (0.76-2.01)           0.361
  Age of more than 75 years                       1.15 (0.83-1.59)           0.396
  ASA score of 4 or 5                             2.20 (1.55-3.15)           \<0.001
  APACHE II score of more than 25                 1.11 (1.08-1.14)           \<0.001
  ICU stay of more than 3 days                    0.54 (0.38-0.79)           0.001
  Re-admission to the ICU                         1.79 (1.21-2.64)           0.004
  Renal failure, hemofiltration within ICU stay   11.99 (8.02-17.92)         \<0.001

APACHE II, Acute Physiology and Chronic Health Evaluation II; ASA, American Society of Anesthesiologists; CI, confidence interval; ICU, intensive care unit.

APACHE score of more than 25 (hazard ratio (HR) 1.1; *P* \<0.001), ASA score of 4 or 5 (HR 2.2; *P* \<0.001), ICU re-admission (HR 1.8; *P* = 0.004), requirement of renal replacement therapy (HR 11.9; *P* \<0.001), and an ICU stay of longer than 3 days (HR 0.5; *P* = 0.001) were identified as mortality-predicting variables in a multivariate Cox regression analysis. For the administration of etomidate, body mass index (BMI) of more than 40 kg/m^2^, age of more than 75 years, and gender Cox analysis showed no significant influence on mortality (Table [5](#T5){ref-type="table"}).

Discussion
==========

Key clinical outcome variables in patients with and without etomidate-facilitated anesthesia induction ahead of major cardiac surgery were comparable and showed no statistically significant differences. The demographic and preoperative data of our cohort indicate a good comparability of the two study groups as there are no statistical differences in age, BMI, APACHE II score, ASA status distribution, and preoperative blood test results. The higher frequency of female patients in the etomidate group is statistically significant but clinically of limited relevance. Little is known about gender differences in postoperative outcome after major cardiac surgery. The literature describes female gender as a risk factor for poor outcome after cardiac surgery because women are usually much older than male patients when undergoing major cardiac surgery \[[@B28],[@B29]\]. The statistically higher rate of etomidate use in patients undergoing emergency cardiac surgery is remarkable. This is most likely due to the fact that emergency patients are more frequently in unstable hemodynamic conditions and preoperative fastening could not be awaited, so that a rapid sequence induction demands a short-onset of the anesthetic drug. The higher rate of emergency procedures in the etomidate group might also be causative for the slight increase of preoperative CK in this group.

Multivariate analysis identified high Mallampati score and male gender as risk factors for poor direct laryngoscopy. Patients who received etomidate for anesthesia induction showed significantly better intubation conditions than patients with an alternative induction regime, which is also reported by a former study \[[@B30]\]. Vasopressor requirements, duration of surgery, and aortic clamping and bypass times showed no significant difference between the two study groups.

The hypothesis of this study was that anesthesia induction using etomidate might lead to poorer clinical outcome due to impaired immune response. This comes along with higher vulnerability for infections and consecutively increased inflammatory serum parameters like CRP, PCT, and leukocyte count. Statistical processing is focused on relative differences between the study groups instead of deviation from normal values in order to account for the inherent inflammation associated with on-pump cardiac surgery. A recently published study showed that PCT is reliable in predicting severity of multi-organ failure and outcome of systemic inflammatory response \[[@B31]\]. In our study, none of the inflammation blood parameters shows a significant difference between the etomidate and the non-etomidate groups in the 5-day course we observed. To the best of our knowledge, no former study has evaluated the effect of etomidate on CRP, PCT, and leukocytes in cardiac surgery patients before.

SOFA score is a reliable and approved sepsis-associated score to reflect multi-organ failure, severity, and outcome in patients with sepsis \[[@B24],[@B32],[@B33]\]. In the present dataset, this score was documented when patients stayed longer than 24 hours in the ICU. We observed the SOFA score for five consecutive days and found no significant difference on any day between the etomidate and the non-etomidate groups. Renal dysfunction and failure constitute one of the most common organ dysfunctions in patients with sepsis \[[@B34],[@B35]\] and are also associated with major cardiac surgery \[[@B36]\]. In the present study, we analyzed the rate of patients requiring renal replacement therapy as well as the hemodialysis hours per patient with renal failure. Neither the rate of patients needing hemodialysis nor the duration of hemodialysis (if required) showed statistically different results in the etomidate and the non-etomidate group. If etomidate administration for anesthesia induction ahead of cardiac surgery would have impaired the clinical outcome, mechanical ventilation hours should also be increased in this group. However, we found no evidence that single-dose use of etomidate ahead of major cardiac surgery increases the duration of mechanical ventilation. Our results are in line with a comparable analysis by Wagner and colleagues in which a prolonged mechanical ventilation time after administration of etomidate in patients undergoing coronary bypass surgery was not reported \[[@B21]\]. Additionally, a single dose of etomidate in patients with sepsis did not lead to an increased mechanical ventilation time \[[@B13]\]. In summary, we found no evidence that a single dose of etomidate for induction of anesthesia increased the risk of postoperative mortality or morbidity.

In patients who already have sepsis, the discussion of whether single-dose etomidate increases mortality risk is controversial. Some retrospective analyses suggested an increased risk of mortality in septic patients who received etomidate for intubation \[[@B5],[@B6],[@B9],[@B32]\]. In contrast to these reports, other studies deny an increased risk of mortality for septic patients who received etomidate \[[@B10],[@B12]-[@B16]\]. It could be hypothesized that cardiac surgery patients with severe comorbidities and impaired ventricular function should more likely have etomidate-triggered adrenal insufficiency and consecutive poor outcome. However, in our cohort, we found no evidence that etomidate leads to increased early or late ICU mortality. Even the total in-hospital mortality showed no difference. Moreover, neither the total length of stay in the ICU nor the total hospital stay differs significantly between the etomidate and the non-etomidate group. Patients of the non-etomidate group show a significantly higher ICU discharge on the first postoperative day. However, on day 2, the discharge rate is already balanced and remains balanced until the end of observation on day 5. The higher rate of emergency interventions in the etomidate group might be causative for a lower discharge rate on postoperative day 1. This theory is supported by the significantly higher peak of CK in the etomidate group which might be higher after myocardial infarction and emergency cardiac surgery. In regard to re-admission to the ICU, our study found no evidence that etomidate given ahead of cardiac surgery leads to a higher ICU re-admission rate. Given all of the postoperative items, the etomidate group showed no statistically significant or clinically relevant poorer outcome in any of the observed variables.

However, our study has some limitations which are based mainly on the retrospective design of the analysis. Owing to missing data in the pre- and postoperative serum test results, these items could not be taken into account for the Cox analysis. The SOFA and APACHE II scores show missing data and were not taken into account for the Cox analysis. The SOFA score was documented only for patients with more than 24 hours in the ICU. Cases which were discharged in the morning after surgery lack of SOFA score. APACHE II score was obtained when preoperative data were available. Where patients were transferred from external wards, these datasets were not available and APACHE II score could not be obtained.

Owing to its retrospective character, the study lacks a randomization protocol. Although the selection of induction regime with or without etomidate was based on the personal preferences of the attending anesthesiologist, a high number of anesthesiologists (135) performing the anesthesia procedures of the study might preclude a selection bias.

Conclusions
===========

This study found no evidence for differences in key clinical outcome parameters based on anesthesia induction with or without administration of a single dose of etomidate. This holds particularly true for mortality, length of hospital stay, length of ICU stay, re-admission to the ICU, duration of mechanical ventilation, postoperative systemic inflammatory response or sepsis discriminated by inflammatory parameters, renal failure, or SOFA score. Moreover, multivariate analysis revealed better intubation conditions in the etomidate group. Despite the known and undisputable risk of adrenal suppression and taking the beneficial effects for hemodynamic unstable and cardiac impaired patients into account, etomidate should remain an acceptable option in clinical routine for anesthesia induction.

Key messages
============

Single-dose etomidate ahead of major on-pump cardiac surgery

● is not associated with higher postoperative mortality.

● is not associated with an increased rate of postoperative infection discriminated by serum tests and morbidity scores.

● is not associated with a higher SOFA score or an increased rate of renal replacement therapy.

● does not change length of ICU or total hospital stay.
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